Santen Buys Asia, Europe Rights To Merck's Eye Drugs For $600 Million
This article was originally published in PharmAsia News
Santen Pharmaceutical has licensed eye drugs from Merck for $600 million upfront, plus milestone payments and royalties, to market them in the Asia Pacific region and in Europe.
You may also be interested in...
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.